Perimenopausal Female: Bleeding >7 Days with Anemia

Definition & Classification

PALM-COEIN: Causes to Consider

In patients >40 years but not yet postmenopausal, anovulatory bleeding due to perimenopause is most likely, but endometrial carcinoma or hyperplasia and leiomyoma must be actively excluded - Rosen's Emergency Medicine

Why Anovulation Drives Perimenopausal AUB

• No corpus luteum forms → no progesterone secretion
• Estrogen continues to stimulate endometrial proliferation unopposed
• The thickened endometrium sheds irregularly, erratically, and heavily
• Prolonged amenorrhea followed by heavy bleeding is the classic pattern
• Chronically increases risk of endometrial hyperplasia and adenocarcinoma

Evaluation

Initial Assessment (for any patient)

• Hemodynamic stability first - examine for signs of hypovolemia/anemia (pallor, tachycardia, BP)
• Rule out pregnancy (urine/serum β-hCG) - always, even in perimenopause

Laboratory Workup

Imaging

• Transvaginal ultrasound (TVUS): first-line imaging
  • Identifies fibroids, polyps, endometrial thickening, ovarian pathology
  • Endometrial thickness >4-5 mm in postmenopausal women warrants further evaluation; in perimenopausal women, thickness is more variable but >12 mm is abnormal
• Sonohysterography (saline infusion sonography): better delineation of intracavitary lesions

Endometrial Sampling - Mandatory in This Age Group

• Endometrial biopsy (EMB) is indicated in all perimenopausal women with AUB to exclude endometrial hyperplasia and carcinoma
• Indicated especially with: age >40, obesity, diabetes, hypertension, nulliparity, family history of endometrial/colorectal cancer
• Hysteroscopy with D&C if EMB is inconclusive or inadequate

Management

Acute/Emergency Management (Hemodynamically Unstable or Severe Anemia)

Medical Management (Subacute/Chronic)

Treatment of Associated Iron Deficiency Anemia

• Oral ferrous sulfate 325 mg TID (on empty stomach if tolerated) - first-line
• IV iron sucrose or ferric carboxymaltose if oral iron not tolerated, non-compliant, or severe anemia requiring faster repletion
• Blood transfusion if Hb <7 g/dL or hemodynamically unstable

Surgical Management

• Endometrial ablation: effective for AUB without structural lesions; not suitable if malignancy suspected
• Hysteroscopic myomectomy/polypectomy: for submucosal fibroids or polyps
• Hysterectomy: definitive treatment

Red Flags Requiring Urgent Evaluation

• Hemodynamic instability
• Hb <8 g/dL with ongoing bleeding
• Endometrial thickness >12 mm on TVUS
• Irregular or thickened endometrium
• Postcoital bleeding (suggests cervical/endometrial pathology)
• Associated pelvic pain/mass
• Risk factors for endometrial cancer (obesity, DM, PCOS, nulliparity)

"Perimenopausal and menopausal women with abnormal bleeding should have expedited follow-up for evaluation of possible malignancy." - Rosen's Emergency Medicine

Key Summary

Perimenopausal AUB + Anemia
     ↓
1. Stabilize (fluids, transfusion if needed)
2. Rule out pregnancy
3. CBC, TSH, coags, iron studies
4. TVUS → assess endometrial thickness, structural pathology
5. Endometrial biopsy → exclude hyperplasia/cancer
6. Treat bleeding: TXA ± hormonal therapy (MPA or OCP taper)
7. Treat anemia: oral/IV iron ± transfusion
8. Long-term: LNG-IUD or cyclic progestins
9. If structural cause found → targeted surgical/procedural management

• Rosen's Emergency Medicine: Concepts and Clinical Practice, Chapter 86 (Abnormal Uterine Bleeding)
• Tintinalli's Emergency Medicine: A Comprehensive Study Guide, Chapter 96 (Vaginal Bleeding)

Management of AUB-O (Anovulatory) in a Perimenopausal Woman with Anemia

Step 1: Assess Severity

Step 2: Stop the Acute Bleed

A. Hormonal - First Line

• Monophasic pill containing <35 µg ethinyl estradiol
• 1 pill every 6 hours x 5-7 days (acute heavy bleed) - Goldman-Cecil Medicine
• OR: 1 pill TID x 7 days; or 1 pill BID x 5 days then OD for rest of pack
• Bleeding should cease within 24-72 hours
• ⚠️ Warn the patient: heavy withdrawal bleed expected 2-4 days after stopping
• After acute control: transition to cyclic OCP (1 pill/day) for at least 3 cycles

Contraindications to estrogen (very relevant in perimenopausal women): smokers >35 years, hypertension, VTE/stroke history, active liver disease, thromboembolic disorders, breast cancer, uncontrolled diabetes with vascular disease

• Medroxyprogesterone acetate (MPA):
  • Acute: 20 mg PO TID x 7 days, OR 10 mg OD x 10 days
  • Bleeding stops in >3 days typically
  • Simultaneously with IV estrogen in severe cases
• After acute episode: cyclic MPA (days 14-28 of cycle) for long-term management

B. Non-Hormonal Adjunct

• Acute IV: 1.0-1.3 g IV, effective within ~3 hours; can continue PO TID
• Ongoing: 1.3 g PO TID during days of heavy bleeding only
• FDA-approved for menorrhagia
• Reduces menstrual blood loss significantly; does not affect cycle regularity
• ⚠️ Contraindicated in VTE/thrombophilia history

• Naproxen 500 mg BID, OR Ibuprofen 400 mg every 6 hours, OR Mefenamic acid 500 mg TID
• Reduce blood loss 30-50% by inhibiting prostaglandins
• Use during days of heavy flow; less potent than TXA or LNG-IUD
• Caution: GI disease, renal disease, bleeding disorders

Step 3: Long-Term Maintenance (Prevent Recurrence)

Step 4: Treat Iron Deficiency Anemia

Summary Algorithm

Perimenopausal AUB-O (no structural cause) + Anemia
             ↓
      Hemodynamically stable?
       YES ──────────────────→ NO → Resuscitate + IV estrogen + IV TXA
        ↓
  Estrogen contraindicated?
       NO → Combined OCP taper (TID x7 days)
      YES → MPA 20 mg TID x7 days (or 10 mg OD x10 days)
        ↓
  Bleeding controlled → Withdrawal bleed expected (warn patient)
        ↓
  Long-term:
  - LNG-IUD (first preference) OR cyclic progestins/OCP
  - TXA ± NSAIDs each cycle if non-hormonal preferred
        ↓
  Treat anemia:
  - Oral ferrous sulfate TID (ongoing)
  - IV iron if severe or oral not tolerated
        ↓
  Follow-up: Repeat CBC at 4-6 weeks; gynecology review

"Anovulatory bleeding in the reproductive-age female increases the risk of endometrial hyperplasia and adenocarcinoma" - even after structural causes are excluded, cyclic progestin or LNG-IUD is mandatory to protect the endometrium from ongoing unopposed estrogen. - Tintinalli's Emergency Medicine

• Goldman-Cecil Medicine, Chapter 220 (Abnormal Uterine Bleeding - Treatment)
• Tintinalli's Emergency Medicine, Chapter 96 (Table 96-4: Treatment of Heavy Vaginal Bleeding)
• Rosen's Emergency Medicine, Chapter 30 & 86 (Pharmacologic Treatment Regimens for AUB)
• Berek & Novak's Gynecology, Nonsurgical Management of AUB